User login
Dr Elaine Siegfried, an expert in pediatric dermatology in St. Louis, Missouri, examines some of the key data and research highlights in atopic dermatitis presented at the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting.
Dr Siegfried starts with two studies on the selective JAK1 inhibitor abrocitinib, in which results in both adults and adolescents confirm the efficacy of the 200 mg dose. However, she cautions that the jury is still out on the long-term safety for this class of drugs.
She then reviews two studies looking at whether individuals with atopic dermatitis who are hospitalized with COVID-19 suffer more severe outcomes than the general population.
Dr Siegfried's final selections focus on food allergy, an important aspect of management in patients with atopic dermatitis.
The first two look at the outcomes of food challenges in shrimp-sensitized children and those with a history suggestive of milk allergy.
The last three studies examine the latest data on an oral immunotherapy peanut allergen powder (Palforzia) approved by the FDA and some of the nonclinical factors that could hamper its uptake.
--
Director, Division of Pediatric Dermatology, Cardinal Glennon Children's Hospital, Saint Louis University Health Sciences Center; Owner, Director, Kids Dermatology, St. Louis, Missouri
Elaine C. Siegfried, MD, has disclosed the following relevant financial relationships:
Contracted research from: AI Therapeutics.
Received consulting fees from: Boehringer Ingelheim; Incyte; Regeneron; Sanofi Genzyme; UCB; AbbVie; Verrica; Leo; Novan; Novartis; Pfizer; Pierre Fabre
Received honoraria from: Regeneron; Sanofi Genzyme; Verrica.
Received fees to SSM/SLU related to sponsoring clinical trials from: Regeneron; Verrica; Pierre Fabre; Janssen; Eli Lilly and Company.
Served on the Data Safety Monitoring Board for: UCB; Leo; Pfizer; Novan.
Received grant funding to support 2020-2022 Peds Derm Fellow from: Pfizer.
Dr Elaine Siegfried, an expert in pediatric dermatology in St. Louis, Missouri, examines some of the key data and research highlights in atopic dermatitis presented at the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting.
Dr Siegfried starts with two studies on the selective JAK1 inhibitor abrocitinib, in which results in both adults and adolescents confirm the efficacy of the 200 mg dose. However, she cautions that the jury is still out on the long-term safety for this class of drugs.
She then reviews two studies looking at whether individuals with atopic dermatitis who are hospitalized with COVID-19 suffer more severe outcomes than the general population.
Dr Siegfried's final selections focus on food allergy, an important aspect of management in patients with atopic dermatitis.
The first two look at the outcomes of food challenges in shrimp-sensitized children and those with a history suggestive of milk allergy.
The last three studies examine the latest data on an oral immunotherapy peanut allergen powder (Palforzia) approved by the FDA and some of the nonclinical factors that could hamper its uptake.
--
Director, Division of Pediatric Dermatology, Cardinal Glennon Children's Hospital, Saint Louis University Health Sciences Center; Owner, Director, Kids Dermatology, St. Louis, Missouri
Elaine C. Siegfried, MD, has disclosed the following relevant financial relationships:
Contracted research from: AI Therapeutics.
Received consulting fees from: Boehringer Ingelheim; Incyte; Regeneron; Sanofi Genzyme; UCB; AbbVie; Verrica; Leo; Novan; Novartis; Pfizer; Pierre Fabre
Received honoraria from: Regeneron; Sanofi Genzyme; Verrica.
Received fees to SSM/SLU related to sponsoring clinical trials from: Regeneron; Verrica; Pierre Fabre; Janssen; Eli Lilly and Company.
Served on the Data Safety Monitoring Board for: UCB; Leo; Pfizer; Novan.
Received grant funding to support 2020-2022 Peds Derm Fellow from: Pfizer.
Dr Elaine Siegfried, an expert in pediatric dermatology in St. Louis, Missouri, examines some of the key data and research highlights in atopic dermatitis presented at the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting.
Dr Siegfried starts with two studies on the selective JAK1 inhibitor abrocitinib, in which results in both adults and adolescents confirm the efficacy of the 200 mg dose. However, she cautions that the jury is still out on the long-term safety for this class of drugs.
She then reviews two studies looking at whether individuals with atopic dermatitis who are hospitalized with COVID-19 suffer more severe outcomes than the general population.
Dr Siegfried's final selections focus on food allergy, an important aspect of management in patients with atopic dermatitis.
The first two look at the outcomes of food challenges in shrimp-sensitized children and those with a history suggestive of milk allergy.
The last three studies examine the latest data on an oral immunotherapy peanut allergen powder (Palforzia) approved by the FDA and some of the nonclinical factors that could hamper its uptake.
--
Director, Division of Pediatric Dermatology, Cardinal Glennon Children's Hospital, Saint Louis University Health Sciences Center; Owner, Director, Kids Dermatology, St. Louis, Missouri
Elaine C. Siegfried, MD, has disclosed the following relevant financial relationships:
Contracted research from: AI Therapeutics.
Received consulting fees from: Boehringer Ingelheim; Incyte; Regeneron; Sanofi Genzyme; UCB; AbbVie; Verrica; Leo; Novan; Novartis; Pfizer; Pierre Fabre
Received honoraria from: Regeneron; Sanofi Genzyme; Verrica.
Received fees to SSM/SLU related to sponsoring clinical trials from: Regeneron; Verrica; Pierre Fabre; Janssen; Eli Lilly and Company.
Served on the Data Safety Monitoring Board for: UCB; Leo; Pfizer; Novan.
Received grant funding to support 2020-2022 Peds Derm Fellow from: Pfizer.
